Research programme : antibody therapeutics - Abveris/Merck & Co
Latest Information Update: 20 Jun 2023
At a glance
- Originator Abveris; Prometheus Biosciences
- Developer Abveris; Merck & Co
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders